

Introduction of new cholesterol therapies and their impact on drug plans

Over the last two years, there has been a significant change to the pharmaceutical benefits landscape due to specialty drugs.

As we told you in the latest Focus Update on [high cost drugs](#), the rapidly evolving specialty drug market has created a need for extra vigilance in managing drug plan costs. New cholesterol drugs, called PCSK9 inhibitors, are the latest entrants to the specialty drugs market and are expected to make a sizeable impact. Given the high prevalence of cholesterol-lowering treatments, it is expected that there will be high sales of PCSK9 inhibitors, once they become available.

Sun Life has prepared [an article](#) to help you understand the new cholesterol therapy, its potential impact on drug plan costs, and how the Enhanced Prior Authorization program can be a solution to manage these costs.

Questions?

Contact your Sun Life Financial group benefits representative.